At last, some good news for hard-pressed Valeant Pharmaceuticals International Inc., with the US FDA announcing the approval of the psoriasis therapy, Siliq (brodalumab), on Feb. 15. The Canada-based multinational said it would start marketing Siliq in the US in the second half of 2017.
Brodalumab was approved in the US for the treatment of adults with moderate-to-severe plaque psoriasis, in patients who are candidates for systemic therapy or phototherapy and have failed to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?